Data shows that cannabis stocks significantly outperformed major indexes in 2016, which is a result of speculative investment based on anticipated expansion of new legal markets. New Frontier reported that the Viridian Cannabis Stock Index gained 236.1% while outperforming such mainstream indexes as the Russell 2000 (up 19.5%), the Dow Jones Industrial Average (up 13.4%), […]

Doctors who treat Dravet syndrome can’t stop their patients’ seizures—but a chemical in weed may help. Dravet syndrome is a rare, genetic form of epilepsy that affects less than one in 16,000 children. It’s diagnosed when infants who are perfectly healthy start having seizures around their first birthday. From there, doctors can prescribe medications that […]

LONDON, June 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that GW management will present at the Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, 14 June at 11:20 a.m. […]

Melissa Mentele,a 40-year old mother of three, worked in healthcare for 20 years until she suffered a catastrophic injury while helping an Alzheimer’s patient out of bed, later developing a rare, “devastating” chronic pain condition called RSD/CRPS. After finding that medical cannabis worked wonders for her pain relief without the “dangerous and debilitating” side effects […]

Medical marijuana is legal in 26 states, the District of Columbia and Guam. Proponents of marijuana, backed by several studies, say the drug has many therapeutic uses. Opponents — and the U.S. government — however, say it has a high potential for abuse and no legitimate therapeutic value. Marijuana’s medicinal uses can be traced back […]

Medical cannabis has gained widespread acceptance throughout North America, but many physicians are still hesitant to prescribe the drug without evidence from clinical trials. While many companies are developing synthetic drugs based on cannabinoids, there are some companies that remain committed to realizing the synergistic capabilities of the whole cannabis plant and proving its therapeutic […]

One of the benefits resulting from the wave of cannabis legalization that is sweeping across North America and other parts of the world, is the increased acceptance, recognition, and acknowledgement by prominent physicians and researchers that there may be viable therapeutic potential for cannabinoids, including THC and also cannabidiol (“CBD”). This has led to a wide […]

Top-line data from this study remains on track to report in September 2017 Devon, PA (GLOBE NEWSWIRE) – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that it has met its enrollment target of 16 patients in its Phase 2 FAB-C (Treatment […]

Medical marijuana is legal in 26 states, the District of Columbia and Guam. Proponents of marijuana, backed by several studies, say the drug has many therapeutic uses. Opponents — and the U.S. government — however, say it has a high potential for abuse and no legitimate therapeutic value. Marijuana’s medicinal uses can be traced back […]

A large clinical trial conducted on a drug derived from cannabis has demonstrated reduction of convulsive seizures experienced by children with a severe form of epilepsy by nearly 50%[1]. The results, published in the New England Journal of Medicine (online, 25 May 2017), has generated interest from the mainstream media. The multicentre international trial randomised 120 […]

DEVON, Pa., June 08, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that it has met its enrollment target of 16 patients in its Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) […]